238 related articles for article (PubMed ID: 10411585)
21. Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia.
Olincy A; Harris JG; Johnson LL; Pender V; Kongs S; Allensworth D; Ellis J; Zerbe GO; Leonard S; Stevens KE; Stevens JO; Martin L; Adler LE; Soti F; Kem WR; Freedman R
Arch Gen Psychiatry; 2006 Jun; 63(6):630-8. PubMed ID: 16754836
[TBL] [Abstract][Full Text] [Related]
22. Effect of R3487/MEM3454, a novel nicotinic alpha7 receptor partial agonist and 5-HT3 antagonist on sustained attention in rats.
Rezvani AH; Kholdebarin E; Brucato FH; Callahan PM; Lowe DA; Levin ED
Prog Neuropsychopharmacol Biol Psychiatry; 2009 Mar; 33(2):269-75. PubMed ID: 19110025
[TBL] [Abstract][Full Text] [Related]
23. Attention and executive function deficits in chronic low-dose MPTP-treated non-human primates.
Decamp E; Schneider JS
Eur J Neurosci; 2004 Sep; 20(5):1371-8. PubMed ID: 15341609
[TBL] [Abstract][Full Text] [Related]
24. Effects of nicotine and mecamylamine on choice accuracy in an operant visual signal detection task in female rats.
Rezvani AH; Bushnell PJ; Levin ED
Psychopharmacology (Berl); 2002 Dec; 164(4):369-75. PubMed ID: 12457266
[TBL] [Abstract][Full Text] [Related]
25. Prefrontal cortex lesions and scopolamine impair attention performance of C57BL/6 mice in a novel 2-choice visual discrimination task.
Dillon GM; Shelton D; McKinney AP; Caniga M; Marcus JN; Ferguson MT; Kornecook TJ; Dodart JC
Behav Brain Res; 2009 Dec; 204(1):67-76. PubMed ID: 19416740
[TBL] [Abstract][Full Text] [Related]
26. Task persistence and learning ability in normal and chronic low dose MPTP-treated monkeys.
Roeltgen DP; Schneider JS
Behav Brain Res; 1994 Feb; 60(2):115-24. PubMed ID: 8003241
[TBL] [Abstract][Full Text] [Related]
27. Nicotine improves performance in an attentional set shifting task in rats.
Allison C; Shoaib M
Neuropharmacology; 2013 Jan; 64():314-20. PubMed ID: 22776507
[TBL] [Abstract][Full Text] [Related]
28. A reversible model of the cognitive impairment associated with schizophrenia in monkeys: potential therapeutic effects of two nicotinic acetylcholine receptor agonists.
Buccafusco JJ; Terry AV
Biochem Pharmacol; 2009 Oct; 78(7):852-62. PubMed ID: 19577545
[TBL] [Abstract][Full Text] [Related]
29. Chronic oral nicotine treatment protects against striatal degeneration in MPTP-treated primates.
Quik M; Parameswaran N; McCallum SE; Bordia T; Bao S; McCormack A; Kim A; Tyndale RF; Langston JW; Di Monte DA
J Neurochem; 2006 Sep; 98(6):1866-75. PubMed ID: 16882311
[TBL] [Abstract][Full Text] [Related]
30. Chronic nicotine interactions with clozapine and risperidone and attentional function in rats.
Rezvani AH; Caldwell DP; Levin ED
Prog Neuropsychopharmacol Biol Psychiatry; 2006 Mar; 30(2):190-7. PubMed ID: 16310917
[TBL] [Abstract][Full Text] [Related]
31. Levodopa improves motor deficits but can further disrupt cognition in a macaque Parkinson model.
Schneider JS; Pioli EY; Jianzhong Y; Li Q; Bezard E
Mov Disord; 2013 May; 28(5):663-7. PubMed ID: 23238827
[TBL] [Abstract][Full Text] [Related]
32. Acute nicotine improves cognitive deficits in young adults with attention-deficit/hyperactivity disorder.
Potter AS; Newhouse PA
Pharmacol Biochem Behav; 2008 Feb; 88(4):407-17. PubMed ID: 18022679
[TBL] [Abstract][Full Text] [Related]
33. Delayed matching-to-sample, object retrieval, and discrimination reversal deficits in chronic low dose MPTP-treated monkeys.
Schneider JS; Roeltgen DP
Brain Res; 1993 Jul; 615(2):351-4. PubMed ID: 8364742
[TBL] [Abstract][Full Text] [Related]
34. Differing effects of N-methyl-D-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-methyl-4-phenyl-tetrahydropyridine monkeys.
Blanchet PJ; Konitsiotis S; Whittemore ER; Zhou ZL; Woodward RM; Chase TN
J Pharmacol Exp Ther; 1999 Sep; 290(3):1034-40. PubMed ID: 10454475
[TBL] [Abstract][Full Text] [Related]
35. Prevention of dyskinesia by an NMDA receptor antagonist in MPTP monkeys: effect on adenosine A2A receptors.
Morissette M; Dridi M; Calon F; Hadj Tahar A; Meltzer LT; Bédard PJ; Di Paolo T
Synapse; 2006 Sep; 60(3):239-50. PubMed ID: 16739115
[TBL] [Abstract][Full Text] [Related]
36. Effects of (+/-)-4-[[2-(1-methyl-2-pyrrolidinyl)ethyl]thio]phenol hydrochloride (SIB-1553A), a selective ligand for nicotinic acetylcholine receptors, in tests of visual attention and distractibility in rats and monkeys.
Terry AV; Risbrough VB; Buccafusco JJ; Menzaghi F
J Pharmacol Exp Ther; 2002 Apr; 301(1):284-92. PubMed ID: 11907185
[TBL] [Abstract][Full Text] [Related]
37. Nicotine improves learning and memory in rats: morphological evidence for acetylcholine involvement.
Uzüm G; Díler AS; Bahçekapili N; Tasyüreklí M; Zíylan YZ
Int J Neurosci; 2004 Sep; 114(9):1163-79. PubMed ID: 15370181
[TBL] [Abstract][Full Text] [Related]
38. Neonatal nicotine exposure impairs nicotinic enhancement of central auditory processing and auditory learning in adult rats.
Liang K; Poytress BS; Chen Y; Leslie FM; Weinberger NM; Metherate R
Eur J Neurosci; 2006 Aug; 24(3):857-66. PubMed ID: 16848798
[TBL] [Abstract][Full Text] [Related]
39. Enhancing effects of nicotine and impairing effects of scopolamine on distinct aspects of performance in computerized attention and working memory tasks in marmoset monkeys.
Spinelli S; Ballard T; Feldon J; Higgins GA; Pryce CR
Neuropharmacology; 2006 Aug; 51(2):238-50. PubMed ID: 16678864
[TBL] [Abstract][Full Text] [Related]
40. Effects of transdermal nicotine on attention in adult non-smokers with and without attentional deficits.
Poltavski DV; Petros T
Physiol Behav; 2006 Mar; 87(3):614-24. PubMed ID: 16466655
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
